MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596807 | Name: Somatotropin (6-13)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Somatotropin (6-13) is a growth hormone.

Chemical Structure

Somatotropin (6-13)
Somatotropin (6-13)
CAS#55207-83-5

Theoretical Analysis

MedKoo Cat#: 596807

Name: Somatotropin (6-13)

CAS#: 55207-83-5

Chemical Formula: C41H66N12O13

Exact Mass: 934.4872

Molecular Weight: 935.05

Elemental Analysis: C, 52.67; H, 7.11; N, 17.98; O, 22.24

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Somatotropin (6-13); Human growth hormone (6-13);
IUPAC/Chemical Name
(2S,5S,8S,11S,14S,17S,20S,23S)-23-amino-5-(2-amino-2-oxoethyl)-11-benzyl-8-(carboxymethyl)-17-(3-guanidinopropyl)-20-(hydroxymethyl)-14-isobutyl-2,25-dimethyl-4,7,10,13,16,19,22-heptaoxo-3,6,9,12,15,18,21-heptaazahexacosanoic acid
InChi Key
FBZGGPWZOUYLLV-IUKVLHSWSA-N
InChi Code
InChI=1S/C41H66N12O13/c1-20(2)14-24(42)33(58)53-30(19-54)39(64)48-25(12-9-13-46-41(44)45)34(59)49-26(15-21(3)4)36(61)50-27(16-23-10-7-6-8-11-23)37(62)52-29(18-32(56)57)38(63)51-28(17-31(43)55)35(60)47-22(5)40(65)66/h6-8,10-11,20-22,24-30,54H,9,12-19,42H2,1-5H3,(H2,43,55)(H,47,60)(H,48,64)(H,49,59)(H,50,61)(H,51,63)(H,52,62)(H,53,58)(H,56,57)(H,65,66)(H4,44,45,46)/t22-,24-,25-,26-,27-,28-,29-,30-/m0/s1
SMILES Code
C[C@@H](C(O)=O)NC([C@H](CC(N)=O)NC([C@H](CC(O)=O)NC([C@H](CC1=CC=CC=C1)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](CO)NC([C@H](CC(C)C)N)=O)=O)=O)=O)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 935.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Reinhard M, Frystyk J, Randers E, Bibby BM, Ivarsen P. Postprandial Mineral Handling in Patients on Maintenance Hemodialysis. J Ren Nutr. 2018 May;28(3):175-182. doi: 10.1053/j.jrn.2017.11.003. Epub 2018 Feb 21. PubMed PMID: 29429792. 2: Radetti G, Elsedfy HH, Khalaf R, Meazza C, Pagani S, El Kholy M, Albertini R, De Stefano AM, Navarra A, De Silvestri A, Bozzola M. Pegvisomant-primed growth hormone (GH) stimulation test is useful in identifying true GH deficient children. Hormones (Athens). 2017 Jul;16(3):291-296. doi: 10.14310/horm.2002.1748. PubMed PMID: 29278515. 3: Pihlainen K, Santtila M, Vasankari T, Häkkinen K, Kyröläinen H. Evaluation of occupational physical load during 6-month international crisis management operation. Int J Occup Med Environ Health. 2018 Jan 7;31(2):185-197. doi: 10.13075/ijomeh.1896.01048. Epub 2017 Oct 2. PubMed PMID: 28972598. 4: Nassiri AA, Hakemi MS, Safar-Pour R, Ahmadi A, Tohidi M, Kashani BS, Esfehani F, Alatab S. Association of serum intact fibroblast growth factor 23 with left ventricular mass and different echocardiographic findings in patients on hemodialysis. J Transl Int Med. 2016 Sep 1;4(3):135-141. doi: 10.1515/jtim-2016-0030. Epub 2016 Sep 23. PubMed PMID: 28191535; PubMed Central PMCID: PMC5290884. 5: Zhu S, Wang Q, Jiang J, Luo Y, Sun Z. A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer. Sci Rep. 2016 Sep 22;6:33894. doi: 10.1038/srep33894. PubMed PMID: 27654169; PubMed Central PMCID: PMC5032167. 6: Prat A, Cheang MC, Galván P, Nuciforo P, Paré L, Adamo B, Muñoz M, Viladot M, Press MF, Gagnon R, Ellis C, Johnston S. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. JAMA Oncol. 2016 Oct 1;2(10):1287-1294. doi: 10.1001/jamaoncol.2016.0922. PubMed PMID: 27281556. 7: Huang H, Wang CQ, Tian QJ. Clinical features and management of 33 patients with 46,XX pure gonadal dysgenesis. Gynecol Endocrinol. 2016 Dec;32(12):995-998. Epub 2016 Jun 2. PubMed PMID: 27250571. 8: Välimäki N, Demir H, Pitkänen E, Kaasinen E, Karppinen A, Kivipelto L, Schalin-Jäntti C, Aaltonen LA, Karhu A. Whole-Genome Sequencing of Growth Hormone (GH)-Secreting Pituitary Adenomas. J Clin Endocrinol Metab. 2015 Oct;100(10):3918-27. doi: 10.1210/jc.2015-3129. Epub 2015 Aug 17. PubMed PMID: 26280510. 9: Cardoso-Weide LC, Cardoso-Penha RC, Costa MW, Ferreira AC, Carvalho DP, Santisteban PS. DuOx2 Promoter Regulation by Hormones, Transcriptional Factors and the Coactivator TAZ. Eur Thyroid J. 2015 Mar;4(1):6-13. doi: 10.1159/000379749. Epub 2015 Mar 7. PubMed PMID: 25960956; PubMed Central PMCID: PMC4404926. 10: Khan KN, Kitajima M, Hiraki K, Fujishita A, Nakashima M, Masuzaki H. Decreased expression of human heat shock protein 70 in the endometria and pathological lesions of women with adenomyosis and uterine myoma after GnRH agonist therapy. Eur J Obstet Gynecol Reprod Biol. 2015 Apr;187:6-13. doi: 10.1016/j.ejogrb.2015.01.012. Epub 2015 Feb 3. PubMed PMID: 25697974. 11: Rousseau AF, Damas P, Ledoux D, Lukas P, Carlisi A, Le Goff C, Gadisseur R, Cavalier E. Vitamin D status after a high dose of cholecalciferol in healthy and burn subjects. Burns. 2015 Aug;41(5):1028-34. doi: 10.1016/j.burns.2014.11.011. Epub 2014 Dec 17. PubMed PMID: 25529268. 12: Søeborg T, Frederiksen H, Mouritsen A, Johannsen TH, Main KM, Jørgensen N, Petersen JH, Andersson AM, Juul A. Sex, age, pubertal development and use of oral contraceptives in relation to serum concentrations of DHEA, DHEAS, 17α-hydroxyprogesterone, Δ4-androstenedione, testosterone and their ratios in children, adolescents and young adults. Clin Chim Acta. 2014 Nov 1;437:6-13. doi: 10.1016/j.cca.2014.06.018. Epub 2014 Jun 27. PubMed PMID: 24976611. 13: Unal OK, Cinkilic N, Gul OO, Cander S, Vatan O, Ersoy C, Yilmaz D, Tuncel E. Investigation of genotoxicity in acromegaly from peripheral blood lymphocyte cultures using a micronucleus assay. J Clin Endocrinol Metab. 2014 Oct;99(10):E2060-6. doi: 10.1210/jc.2014-1641. Epub 2014 Jun 25. PubMed PMID: 24963647. 14: Navardauskaite R, Dusatkova P, Obermannova B, Pfaeffle RW, Blum WF, Adukauskiene D, Smetanina N, Cinek O, Verkauskiene R, Lebl J. High prevalence of PROP1 defects in Lithuania: phenotypic findings in an ethnically homogenous cohort of patients with multiple pituitary hormone deficiency. J Clin Endocrinol Metab. 2014 Jan;99(1):299-306. doi: 10.1210/jc.2013-3090. Epub 2013 Dec 20. PubMed PMID: 24178788. 15: Bayram F, Baskol G, Tanriverdi F, Baskol M, Kocer D, Caniklioğlu A. Paraoxonase is reduced in patients with growth hormone deficiency: A novel risk factor for atherosclerosis. J Res Med Sci. 2013 Apr;18(4):291-6. PubMed PMID: 24124425; PubMed Central PMCID: PMC3793373. 16: Kim JO, Ma R, Akagami R, McKenzie M, Johnson M, Gete E, Nichol A. Long-term outcomes of fractionated stereotactic radiation therapy for pituitary adenomas at the BC Cancer Agency. Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):528-33. doi: 10.1016/j.ijrobp.2013.06.2057. Epub 2013 Aug 14. PubMed PMID: 23953637. 17: Allas S, Abribat T. Clinical perspectives for ghrelin-derived therapeutic products. Endocr Dev. 2013;25:157-66. doi: 10.1159/000346065. Epub 2013 Apr 25. Review. PubMed PMID: 23652401. 18: Grieco P, Carotenuto A, Auriemma L, Limatola A, Di Maro S, Merlino F, Mangoni ML, Luca V, Di Grazia A, Gatti S, Campiglia P, Gomez-Monterrey I, Novellino E, Catania A. Novel α-MSH peptide analogues with broad spectrum antimicrobial activity. PLoS One. 2013 Apr 23;8(4):e61614. doi: 10.1371/journal.pone.0061614. Print 2013. PubMed PMID: 23626703; PubMed Central PMCID: PMC3634028. 19: Massabeau C, Sigal-Zafrani B, Belin L, Savignoni A, Richardson M, Kirova YM, Cohen-Jonathan-Moyal E, Mégnin-Chanet F, Hall J, Fourquet A. The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer? Breast Cancer Res Treat. 2012 Jul;134(1):259-66. doi: 10.1007/s10549-012-2027-3. Epub 2012 Mar 22. PubMed PMID: 22438050. 20: Wang M, Mou C, Jiang M, Han L, Fan S, Huan C, Qu X, Han T, Qu Y, Xu G. The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases. Eur J Endocrinol. 2012 May;166(5):797-802. doi: 10.1530/EJE-11-1119. Epub 2012 Feb 14. PubMed PMID: 22334636.